Antiemetic efficacy and safety of granisetron or palonosetron alone and in combination with a corticosteroid for ABVD therapy-induced nausea and vomiting

Table 3 Number of patients experiencing SEs in palonosetron and granisetron groups

SEs^a	Granisetron (n = 21)	Palonosetron (n = 18)	p value^b
Anorexia	15 (71.4%)	18 (100%)	0.022
Malaise	8 (38.1%)	13 (72.2%)	0.054
Leucopenia	4 (19.1%)	12 (66.7%)	0.004
Neutropenia	3 (14.3%)	12 (66.7%)	0.001
Fever	3 (14.3%)	6 (33.3%)	0.255
Oral mucositis	3 (14.3%)	3 (16.7%)	1.000
Febrile Neutropenia	3 (14.3%)	0 (0%)	0.235
Constipation	2 (9.5%)	5 (27.8%)	0.216
Headache	2 (9.5%)	2 (11.1%)	1.000
Neuropathy	2 (9.5%)	0 (0%)	0.490
Diarrhea	2 (9.5%)	0 (0%)	0.490

^aSide effects (SEs) with frequencies of more than 5% in either group are listed
^bA significant difference is in italics

ISSN: 2055-0294